Verastem Inc (VSTM)

3.230
-0.090(-2.71%)
After Hours
3.200
-0.030(-0.929%)
- Real-time Data
  • Volume:
    941,245
  • Bid/Ask:
    3.200/3.510
  • Day's Range:
    3.205 - 3.340

VSTM Overview

Prev. Close
3.32
Day's Range
3.205-3.34
Revenue
84.48M
Open
3.28
52 wk Range
1.08-4.93
EPS
-0.27
Volume
941,245
Market Cap
555.3M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,790,411
P/E Ratio
-
Beta
0.92
1-Year Change
141.04%
Shares Outstanding
171,919,345
Next Earnings Date
Aug 10, 2021
What is your sentiment on Verastem Inc?
or
Market is currently closed. Voting is open during market hours.

Verastem Inc News

Verastem Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellBuy
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Buy
SummarySellStrong SellStrong SellStrong SellStrong Buy

Verastem Inc Company Profile

Verastem Inc Company Profile

Employees
49

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Read More
  • Any news?
    0
    • TUSK double the price very soon..Very low volume.. Easy to jump.. Don't miss it.. Good luck guys..
      1
      • They are working on a cancer medicine.. Finish the two stages.. Waiting to finish the third stage to fly like a rocket..
        0
        • 3 soon
          0
          • TUSK double the price very soon..
            0
            • Ride or die
              0
              • Oh cousin :) are we on the same ride
                0
            • Someone picked up 1,962,672 at $2.01 yesterday right before close That's $3,959,040.72
              0
              • Buy and hold..1st target 3usd soon.. 2nd target 4usd
                0
                • Lets go up.. I think it takes long enough.. Now time to jump up..
                  0
                  • lol
                    0
                    • omg it's coming back
                      0
                      • Will reach 4.17 very soon
                        1
                        • what going on with this one ...seems to be stuck
                          0
                          • over and over again till they got them on the market.. thats a lot of swings to jump on to in the coming months.
                            8
                            • And after the news all will drop again hopefully again ike now to these 1.3 buying levels
                              0
                              • Verastem will make u rich over and over again..; watch how this is gonna jump to 3-4 on the next news of one of their multiple cancer drugs doing now Phase2 and Phase1 ...  Pow! Pow!! Pow!!!
                                1
                                • i think it was the bottom only way is up now
                                  0
                                  • still waiting
                                    0
                                    • $3 soon
                                      0
                                      • I am hopeful that it will be $3 soon.
                                        0
                                    • Best buy ive seen in my life
                                      5
                                      • Why?
                                        0
                                    • goes back where it belongs somewhere below 1,5 USD
                                      5
                                      • should hold or sell ?
                                        0
                                        • it must climb... very undervalued...👍
                                          0
                                          • You can get a 1$call option expiring 6/19 for 80$ right now. Talk about about easy money. The option basically pays for itself and then some.
                                            1
                                            • hope so
                                              0
                                              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.